Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of 0.00% is 100% above its 5-year average of -187.96%, near the high end of its 5-year range (-55096.77%–5148.39%).
As of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
NET PROFIT MARGIN
0.00%
NET PROFIT MARGIN AVG TTM
0.00%
NET PROFIT MARGIN AVG 3Y
0.00%
NET PROFIT MARGIN AVG 5Y
-187.96%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
+100.00%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.26%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+100.00%
vs the sector median at left
Candel Therapeutics, Inc.
Market Cap
$723.91M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
-187.96%
Market Cap
$723.75M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$714.89M
Net Profit Margin
-170055.93%
TTM Avg
-70304.07%
3Y Avg
-35619.60%
5Y Avg
-24164.90%
Market Cap
$746.36M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$711.33M
Net Profit Margin
5.93%
TTM Avg
9.51%
3Y Avg
5.53%
5Y Avg
9.43%
Market Cap
$699.31M
Net Profit Margin
-38.98%
TTM Avg
-18.01%
3Y Avg
-10.19%
5Y Avg
-2.91%
Market Cap
$691.39M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$692.62M
Net Profit Margin
-309.73%
TTM Avg
-283.95%
3Y Avg
-1263.35%
5Y Avg
-1016.41%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Candel Therapeutics, Inc. (CADL) | $723.91M | 0.00% | 0.00% | 0.00% | -187.96% |
| Achieve Life Sciences, Inc. (ACHV)vs › | $723.75M | 0.00% | 0.00% | 0.00% | 0.00% |
| Avalo Therapeutics, Inc. (AVTX)vs › | $714.89M | -170055.93% | -70304.07% | -35619.60% | -24164.90% |
| Design Therapeutics, Inc. (DSGN)vs › | $746.36M | 0.00% | 0.00% | 0.00% | 0.00% |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $711.33M | 5.93% | 9.51% | 5.53% | 9.43% |
| Apnimed, Inc. (APMD)vs › | $741.11M | N/A | N/A | N/A | N/A |
| Cytek Biosciences, Inc. (CTKB)vs › | $699.31M | -38.98% | -18.01% | -10.19% | -2.91% |
| Faeth Therapeutics, Inc. (FTH)vs › | $691.39M | 0.00% | 0.00% | 0.00% | 0.00% |
| Wave Life Sciences Ltd. (WVE)vs › | $692.62M | -309.73% | -283.95% | -1263.35% | -1016.41% |
| Anteris Technologies Global Corp. (AVR)vs › | $688.40M | -4619.67% | -3871.87% | -2595.36% | -1815.29% |
Operating Margin
0.0%
Net Profit Margin
0.0%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | -16396.77% |
| 2022-09-30 | -28025.81% |
| 2022-06-30 | -13383.87% |
| 2022-03-31 | -2819.35% |
| 2021-12-31 | 5148.39% |
| 2021-09-30 | -52135.48% |
| 2021-06-30 | -55096.77% |
| 2021-03-31 | -14445.16% |
| 2020-12-31 | -33800.00% |
| 2020-09-30 | -8238.71% |
| 2020-06-30 | -9277.42% |
| 2020-03-31 | -5716.13% |
